Related Experiment Video
Updated: Jul 15, 2026
14:20
Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?
Published on: June 13, 2014
16.8K
Asialoglycoprotein Receptor-Targeted Superparamagnetic Perfluorooctylbromide Nanoparticles
Yang Li1, Chao Feng Yang1, Hui Zuo2
1Department of Radiology, The Affiliated Hospital of North Sichuan Medical College, 63 Wenhua Road, Nanchong City, Sichuan Province 637000, China.
Contrast Media & Molecular Imaging
|June 16, 2021
Summary
Researchers developed ASGPR-targeted nanoparticles (GalPLL/M-PFOBNP) for liver imaging. This agent successfully targeted liver cells and enhanced MRI contrast in rats, showing potential for diagnosing liver disease.
Area of Science:
- Nanotechnology
- Biomedical Imaging
- Hepatology
Background:
- Asialoglycoprotein receptor (ASGPR) levels decrease in chronic liver disease and liver tumors.
- Developing targeted contrast agents can aid in diagnosing liver conditions.
Purpose of the Study:
- To create ASGPR-targeted superparamagnetic perfluorooctylbromide nanoparticles (M-PFONP).
- To evaluate the targeting ability of M-PFONP in buffalo rat liver (BRL) cells in vitro.
- To assess the in vivo enhancement of rat liver parenchyma R2 value post-injection.
Main Methods:
- Synthesized ASGPR ligand GalPLL.
- Prepared M-PFOBNP using film hydration and sonication.
- Characterized nanoparticles and assessed safety in vitro; performed in vivo MR T2 mapping.
Main Results:
- Optimized GalPLL/M-PFOBNP contained 52.79 µg/mL Fe3O4 nanoparticles with a mean size of 285.6 nm.
- Confirmed ASGPR specificity using fluorescence microscopy.
- Demonstrated significantly higher R2 value increase in rat liver parenchyma with GalPLL/M-PFOBNP compared to M-PFOBNP.
Conclusions:
- GalPLL/M-PFOBNP exhibits ASGPR specificity and enhances liver MRI contrast.
- This agent shows promise as a liver-targeted contrast agent for MR receptor imaging.
